• 1. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives Isoquinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoquinolines and derivatives

Introduction to 1-bromo-6,7-dimethoxyisoquinoline (CAS No. 949139-74-6)

1-bromo-6,7-dimethoxyisoquinoline, identified by its Chemical Abstracts Service (CAS) number 949139-74-6, is a significant intermediate in the field of organic synthesis and pharmaceutical research. This compound belongs to the isoquinoline family, a class of heterocyclic aromatic organic compounds that have garnered considerable attention due to their diverse biological activities and applications in medicinal chemistry. The presence of both bromine and methoxy substituents in its structure imparts unique reactivity, making it a valuable building block for further chemical transformations.

The structure of 1-bromo-6,7-dimethoxyisoquinoline features a bicyclic system consisting of a benzene ring fused to a pyridine ring, with bromine and methoxy groups strategically positioned. This arrangement not only enhances its synthetic utility but also contributes to its potential pharmacological properties. The bromine atom, in particular, serves as a reactive handle for cross-coupling reactions such as Suzuki-Miyaura and Buchwald-Hartwig couplings, which are pivotal in constructing more complex molecular architectures.

In recent years, there has been growing interest in isoquinoline derivatives due to their demonstrated efficacy in various therapeutic areas. Studies have highlighted the potential of 1-bromo-6,7-dimethoxyisoquinoline as a precursor in the synthesis of bioactive molecules targeting neurological disorders, infectious diseases, and cancer. For instance, modifications of this scaffold have led to the discovery of compounds with inhibitory effects on specific enzymes and receptors involved in pathogenic processes.

One notable application of 1-bromo-6,7-dimethoxyisoquinoline is in the development of antimicrobial agents. Researchers have leveraged its framework to design molecules capable of disrupting bacterial cell wall synthesis or interfering with essential metabolic pathways. The methoxy groups enhance solubility and metabolic stability, while the bromine atom allows for further functionalization via transition-metal-catalyzed reactions. These attributes make it an attractive candidate for drug discovery programs aimed at combating resistant bacterial strains.

The pharmaceutical industry has also explored 1-bromo-6,7-dimethoxyisoquinoline as a starting material for antitumor agents. Isoquinoline derivatives have shown promise in preclinical studies by inhibiting kinases and other enzymes overexpressed in cancer cells. The ability to introduce diverse substituents into the core structure enables fine-tuning of pharmacokinetic properties such as bioavailability and selectivity. This flexibility is crucial for developing next-generation therapeutics with improved efficacy and reduced side effects.

Advances in synthetic methodologies have further expanded the utility of 1-bromo-6,7-dimethoxyisoquinoline. Techniques such as palladium-catalyzed borylation followed by Suzuki coupling allow for the introduction of aryl or heteroaryl groups at specific positions within the isoquinoline ring. Such modifications can significantly alter biological activity by modulating binding interactions with target proteins or enzymes. These innovations underscore the compound's role as a cornerstone in modern medicinal chemistry.

The chemical reactivity of 1-bromo-6,7-dimethoxyisoquinoline also makes it valuable in materials science applications beyond pharmaceuticals. For example, its ability to undergo polymerization or form coordination complexes with metal ions opens doors for developing novel functional materials. These applications are particularly relevant in areas such as organic electronics and catalysis, where tailored molecular architectures are essential for achieving desired performance characteristics.

In conclusion,1-bromo-6,7-dimethoxyisoquinoline (CAS No. 949139-74-6) represents a versatile and highly functional compound with broad applications across multiple scientific disciplines. Its unique structural features and reactivity profile position it as a key intermediate in drug discovery efforts targeting various diseases. As research continues to uncover new synthetic strategies and biological functions,1-bromo-6,7-dimethoxyisoquinoline is poised to remain at the forefront of innovation in organic chemistry and medicinal science.

• 1421517-83-0(1-bromo-4-methoxyisoquinoline)
• 117873-72-0(2,6-Dibromo-4-methoxypyridine)
• 89488-29-9(2-bromo-4-methoxy-pyridine)
• 342411-95-4(2-Bromo-4-methoxyquinoline)
• 1196152-83-6(1-bromo-6-methoxyisoquinoline)
• 1211536-66-1(6-bromo-4-methoxypyridin-3-ol)
• 849132-12-3(1-Bromo-7-methoxyisoquinoline)
• 476161-59-8(2-Bromo-6-methoxyquinoline)
• 1246554-40-4(3-bromo-7-methoxyisoquinoline)
• 862249-70-5(Quinoline, 2-bromo-7-methoxy-)